{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-049085","form_type":"8-K","ticker":"CYTK","cik":"0001061983","company_name":"CYTOKINETICS INC","filed_at":"2024-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.129680+00:00","generated_at":"2026-06-03T06:11:15.944088+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cytokinetics appoints Sung H. Lee as EVP, CFO effective May 8, 2024","bullets":["Annual base salary of $550,000; target bonus 45% of base under corporate bonus plan.","Signing bonus of $80,000; repayable if voluntarily resigns or terminated for cause within 12 months.","Initial equity awards: $1,682,500 RSU, $1,682,500 stock options (Black-Scholes), $1,670,000 performance-based PSU.","Lee replaces CEO Robert I. Blum, who had been serving as interim principal financial officer.","Prior roles include CFO at Vir Biotechnology, MorphoSys AG, and Sangamo Therapeutics."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-049085","json":"https://secwatch.observer/filing/0000950170-24-049085.json","markdown":"https://secwatch.observer/filing/0000950170-24-049085.md","text":"https://secwatch.observer/filing/0000950170-24-049085.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1061983/000095017024049085/0000950170-24-049085-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1061983/000095017024049085/cytk-20240423.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T06:11:15.944088+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7c29b3415b","claim":"Sung H. Lee was appointed as Executive Vice President, Chief Financial Officer at CYTOKINETICS INC.","evidence_excerpt":"On April 23, 2024, Cytokinetics, Incorporated (the “Company”) entered into an employment offer letter (the “Offer Letter”) with Sung H. Lee, pursuant to which Mr. Lee has agreed to serve as the Company’s Executive Vice President (“EVP”), Chief Financial Officer, effective as of May 8, 2024 (the “Start Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017024049085/0000950170-24-049085-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President, Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}